Gastrointestinal stromal tumours (GISTs) are defined as mesenchymal tumours of the gastrointestinal tract that express positivity for CD117, which is a c- KIT proto-oncogene antigen. Expression of the c- KIT protein, a tyrosine kinase growth factor receptor, allows the distinction between GISTs and other mesenchymal tumours such as leiomyoma, leiomyosarcoma, schwannoma and neurofibroma. GISTs can develop anywhere in the gastrointestinal tract, as well as in the mesentery and omentum. Over the years, the management of GISTs has improved due to a better knowledge of their behaviors and risk or recurrence, the identification of specific mutations and the use of targeted therapies. This has resulted in a better prognosis for patients with GISTs. In parallel, imaging of GISTs has been revolutionized by tremendous progress in the field of detection, characterization, survival prediction and monitoring during therapy. Recently, a particular attention has been given to radiomics for the characterization of GISTs using analysis of quantitative imaging features. In addition, radiomics has currently many applications that are developed in conjunction with artificial intelligence with the aim of better characterizing GISTs and providing a more precise assessment of tumour burden. This article sums up recent advances in computed tomography and magnetic resonance imaging of GISTs in the field of image/data acquisition, tumour detection, tumour characterization, treatment response evaluation, and preoperative planning.